The news: CBS is ending “The Late Show with Stephen Colbert” next year, an announcement the titular host made during taping for his Thursday show, sparking controversy and speculation. The move came days after Colbert criticized CBS parent company Paramount on air, saying it paid a “big fat bribe” when settling a lawsuit with Trump worth $16 million. Our take: Though politics and Paramount’s sink-or-swim pending merger may have influenced the swiftness of “The Late Show” cancellation, the ultimate cause likely boils down to the traditional TV model floundering.

The news: Fox News is seeing a rise in ad revenues as advertisers look to curry favor with the Trump administration, per a Financial Times report. Advertisers are hoping to reach “an audience of one,” per Fox’s head of ad sales, after it was revealed that President Trump is a regular viewer of the channel. Our take: Ad spending is becoming increasingly political, influenced by who holds power, what media they consume, and how brands position themselves in a partisan media environment. Brands are increasingly expected to take a stance—even if it means aligning themselves with controversy.

The news: Pharma companies can earn a speedier path to approvals for new drugs if they agree to lower US prices to global levels. The takeaway: Pharma companies are on board with faster drug approvals and higher global prices, but they still make the bulk of their profits on US sales. By adopting good faith balanced stances—advocating for fairer pricing, but highlighting innovation—pharma can notch wins with the administration and consumers.

The news: Linda Yaccarino, CEO of Elon Musk’s X, left the company Wednesday as the social platform faced a major AI controversy—raising questions about the platform’s future and how advertisers will navigate the shift. Yaccarino, who became CEO of X in 2023, announced her decision to leave on Wednesday. Our take: X’s future is increasingly rocky. Yaccarino’s departure reaffirms many advertisers’ fears that the platform is far from stable, and the Grok mishap indicates that it isn’t yet brand safe—meaning major advertisers could retreat once again.

The news: The newly passed Trump federal budget slashes healthcare spending by more than $1 trillion over the next 10 years. The takeaway: The cascading effect of federal spending cuts to Medicaid and ACA is poised to reshape US healthcare with more uninsured patients, lower payments and higher costs for physicians and healthcare systems, rural hospital closings, and increased costs for insurers. We expect advanced cost-cutting measures and lobbying for concessions as the industry braces for the initial effects next year.

The news: TikTok is reportedly exploring a US-only version of the app amid ongoing discussions of a US ban and selloff, per The Information. The new app is said to align with the requirements of the Protecting Americans from Foreign Adversary Controlled Applications Act. Our take: A US-specific app would allow TikTok to potentially regain advertiser confidence in a critical market—but the new app’s success depends on how a new algorithm would impact the user experience.

The news: Paramount has settled a lawsuit with Donald Trump after the president sued the company following a “60 Minutes” interview with Kamala Harris that he argued contained “deceptive doctoring,” the company announced Tuesday. Sources cited by The Hollywood Reporter claim the lawsuit posed a threat to Paramount’s pending merger with Skydance, which will require the Trump administration’s approval. Our take: While the settlement could pave the way for Paramount and Skydance’s merger, it raises questions about the future of media companies who are perceived as holding a liberal bias—and concerns about increasing censorship in the current political environment.

The upshot: The first meeting of a new and controversial CDC vaccine advisory panel signaled its intent to focus on childhood immunizations. The panel may change childhood vaccination approvals and scheduling. Our take: Pharma vaccine makers can’t stay quiet for much longer and can take a page from the medical associations by messaging to consumers and parents that they stand by their products.

The news: The Trump administration is mulling new policies to make pharma advertising more difficult, per a Bloomberg report. Our take: RFK previously acknowledged the First Amendment hurdles in an outright pharma ad ban. But if he takes an alternate path with new D2C ad regulations, it’s a win for the industry. Pharma companies can budget for extra media costs of additional TV time and the loss of ad tax deductions, but they get to keep D2C advertising.

The news: Novo Nordisk missed an important patent filing deadline in Canada for its weight loss and diabetes drug semaglutide, opening the door to generics as soon as next year. Our take: If Sandoz and other generic makers start selling semaglutide GLP-1 drugs in Canada next year, FDA approval for states may not matter. If drugmakers do start selling generic GLP-1s in Canada, Novo will see Ozempic brand sales drop, but the GLP-1 market could see a generics’ explosion.

Tariff uncertainty, billion-dollar merger and acquisition deals, and a jump in social commerce will create new dynamics in the payments industry in H2 2025. Burgeoning tech like agentic AI and stablecoins will further shake up the space.

The news: President Donald Trump is expected to sign another executive order extending TikTok’s sale deadline as the current June 19 deadline approaches, marking the third extension since Trump took office. Our take: Trump is likely to continue extending TikTok’s sale deadline—but with each extension, brand confidence plummets further as the platform’s long term sustainability remains shrouded in uncertainty. The brands that will be most successful aren’t those that are crossing their fingers for TikTok’s survival, but those that are investing in contingency plans and platform-agnostic strategies that can pivot quickly.

The news: Avidity Biosciences struck a deal with the FDA for accelerated approval of a treatment for a rare type of muscular dystrophy. Our take: The Avidity announcement and federal health agency enthusiasm are positive signs for biotech and pharma companies looking for accelerated approval for rare disease candidates. Federal authorities and drugmakers will need to balance speed-to-market with rigorous science to ensure physician and consumer confidence.

The news: WPP Media has lowered its global ad spend forecast for 2025 by 1.7%, reaching 6% compared with the 7.7% projected in December. The downgrade is attributed to ongoing trade wars resulting from President Trump’s current tariff policies, with WPP Media president Kate Scott-Dawkins citing “uncertainty.” Our take: Despite global uncertainty, advertisers who remain flexible with data-informed pivots, prioritize performance marketing, and plan for uncertainty will come out on top.

The news: Monthly subscription dog toy company BarkBox is under fire for a leaked Slack message showing the company stepping back from its Pride marketing initiatives. The message claimed that promoting its Pride offerings alienates a large portion of BarkBox’s audience. Our take: The BarkBox backlash highlights that companies are at an inflection point where submitting to political pressures and pulling back on Pride is just as risky as staying the course—but those who remain committed are most likely to benefit in the long run.

LGBTQ+ influencers note drop in Pride deals: The change, attributed to pressure from the administration, could have consequences for brands.

This decision feeds into the rising enthusiasm for stablecoin as the future of payments.

After a lengthy battle with regulators, banks may be happy to hear these requirements could get another cut.

Charter Communications and Cox will merge: Though the deal could face regulatory scrutiny, it promises to revitalize the ad landscape, if successful.